Elsevier

Brain Research Bulletin

Volume 55, Issue 5, 15 July 2001, Pages 619-624
Brain Research Bulletin

Prodynorphin and κ opioid receptor mRNA expression in the cingulate and prefrontal cortices of subjects diagnosed with schizophrenia or affective disorders

https://doi.org/10.1016/S0361-9230(01)00525-1Get rights and content

Abstract

The present study examined the prodynorphin and κ opioid receptor mRNA expression levels in the anterior cingulate and dorsolateral prefrontal cortices of subjects diagnosed with schizophrenia, bipolar disorder, or major depression as compared with normal controls without a psychiatric diagnosis. Multivariate analyses failed to reveal any differences in the mRNA expression levels between the four diagnostic groups, though a group trend (non-significant) was evident for the expression of the κ opioid receptor and prodynorphin mRNAs in the prefrontal cortex. The mRNA expression levels were not associated with lifetime history of antipsychotic treatment or with suicide as a cause of death. The results, however, suggested an influence of certain drugs of abuse on the prodynorphin cortical mRNA expression. Prodynorphin mRNA expression levels were found to be elevated in individuals with a history of marihuana or stimulant use, but not alcohol. Overall, our data do not provide strong evidence for impaired prodynorphin or κ opioid receptor mRNA levels in the dorsolateral prefrontal or cingulate cortices of schizophrenic, bipolar disorder, or major depressed subjects.

Introduction

Dynorphin opioid neuropeptides and their main receptors, the κ opioid receptors, exhibit a widespread distribution throughout the mammalian brain 10, 15, 18, 26, 27, 30, 32, 35, 46, 54, 60. This opioid neuropeptide system has been implicated in the control of motor, endocrine, and cognitive functions and is intricately linked with dopamine (DA) and serotonin (5-HT) neurotransmitters, which are believed to play a strong role in schizophrenia and depression disorders. Catecholaminergic neurons send terminal projections to dynorphin-containing neuronal populations [56] and influence the activity of the opioid cells. DA agonists increase dynorphin gene expression 17, 19, 24, 41 and protein 41, 45, 47, 59 levels and dynorphin and other κ agonists in their turn decrease DA release 13, 49. It has also been demonstrated that destruction of the raphe nucleus [34], which provides the main serotoninergic innervation of the central nervous system, or pharmacological serotoninergic manipulations [16] alter gene expression in dynorphinergic neurons. Moreover, activation of the κ opioid receptors depresses evoked excitatory postsynaptic potentials of serotonergic cells in the dorsal raphe nucleus [39] and reduces the release of 5-HT [11]. In the human brain, the κ opioid receptor mRNA is expressed in dopaminergic neurons of the substantia nigra as well as in neurons of the raphe nuclei [37].

Several lines of evidence suggest that, in addition to DA and 5-HT, the endogenous dynorphin peptides and the κ opioid receptors may also play a role in the pathophysiology of mental illnesses. Initial studies carried out in the mid-1980s with healthy human volunteers reported psychomimetic and dysphoric effects upon activation of κ opioid receptors 29, 38. Moreover, drugs acting at κ opioid receptors have been shown to have strong antidepressant 7, 14 and antipsychotic [43] effects.

The prefrontal cortex is an important brain area for high-level cognitive and emotional processes. In schizophrenics, a growing body of evidence has been accumulated showing neuropathological, neuropsychological, and cerebral blood flow dysfunction related to the dorsolateral prefrontal cortex 1, 2, 3, 28, 33, 48, 52. Abnormalities have also been reported in the cingulate and prefrontal cortices in subjects with major depression and bipolar disorder 5, 6, 8, 9, 36, 42, 57. Despite the implications of an involvement of the dynorphin/κ opioid receptor cortical system in psychiatric disorder, no studies have directly examined the mRNA expression of either prodynorphin or the κ opioid receptor in individuals with psychiatric illnesses. In the current study, in situ hybridization histochemistry was used to determine the expression levels of the κ opioid receptor and the prodynorphin mRNAs in the anterior cingulate and dorsolateral prefrontal cortices of three groups of patients diagnosed with specific psychiatric disorders and in normal control subjects.

Section snippets

Materials and methods

Dorsolateral prefrontal (Brodmann area 46 and 9) and anterior cingulate (Brodmann area 23) cortical tissues were obtained from the Stanley Foundation Neuropathology Consortium that collected the brains under approved ethical guidelines. Four groups were studied: schizophrenia (n = 14), bipolar disorder (n = 15), major depression without psychotic feature (n = 15), and normal controls (n = 15). The schizophrenic subjects (9 males and 5 females; 12 White and 2 Asian) ranged in age from 25 to 62

Results

The use of the prodynorphin and κ opioid receptor riboprobes resulted in different hybridization patterns with signals expressed only in the cortex and not in the adjacent white matter. In the prefrontal cortex, hybridizations carried out with the prodynorphin riboprobe resulted in a characteristic labeling concentrated to layer IV (Fig. 1C), whereas the κ opioid receptor probe labeled primarily the deeper layer V and VI (Fig. 1D). In the cingulate cortex both probes (though relatively weaker

Discussion

This is the first report regarding prodynorphin and κ opioid receptor mRNA expression levels in the prefrontal and cingulate cortices of subjects with specific psychiatric diagnoses. We confirm the characteristic cortical lamination expression patterns of both mRNAs that has been described previously 21, 37. However, no significant effects of diagnosis on the prodynorphin or κ opioid receptor mRNA levels were detected in either cortical region and none of the psychiatric groups showed evidence

Acknowledgements

This work was funded by the Karolinska Institute, Swedish Medical Research Council (11252), and the Stanley Foundation. Postmortem brains were donated by the Stanley Foundation Brain Consortium courtesy of Drs. Llewellyn B. Bigelow, Juraj Cervenak, Mary M. Herman, Thomas M. Hyde, Joel E. Kleinman, José D. Paltán, Robert M. Post, E. Fuller Torrey, Maree J. Webster, and Robert H. Yolken. We thank Mrs. Barbro Berthelsson and Miss Pia Eriksson for their valuable technical assistance and Elisabeth

References (60)

  • D.J Mason et al.

    A diminution of delta9-tetrahydrocannabinol modulation of dynorphin A-(1-17) in conjunction with tolerance development

    Eur. J. Pharmacol.

    (1999)
  • R Maurer et al.

    Multiple opiate receptor in human brainAn autoradiographic investigation

    Life Sci.

    (1983)
  • B.J Morris et al.

    Regulation of striatal prodynorphin mRNA levels by the raphe-striatal pathway

    Mol. Brain Res.

    (1988)
  • D Peckys et al.

    Expression of mu, kappa, and delta opioid receptor messenger RNA in the human CNSA 33P in situ hybridization study

    Neuroscience

    (1999)
  • R.D Pinnock

    Activation of kappa-opioid receptors depresses electrically evoked excitatory postsynaptic potentials on 5-HT-sensitive neurones in the rat dorsal raphe nucleus in vitro

    Brain Res.

    (1992)
  • P Slater et al.

    Autoradiographic distribution of dynorphin1-9 binding sites in primate brain

    Neuropeptides

    (1986)
  • R Spangler et al.

    ‘Binge’ cocaine administration induces a sustained increase of prodynorphin mRNA in rat caudate-putamen

    Mol. Brain Res.

    (1993)
  • N.C Stefanis et al.

    Elevation of D4 dopamine receptor mRNA in postmortem schizophrenic brain

    Mol. Brain Res.

    (1998)
  • E.F Torrey et al.

    The Stanley Foundation Brain Collection and Neuropathology Consortium

    Schizophr. Res.

    (2000)
  • E.M Unterwald et al.

    Neuroanatomical localization of kappa 1 and kappa 2 opioid receptors in rat and guinea pig brain

    Brain Res.

    (1991)
  • S.P Welch

    Characterization of anandamide-induced toleranceComparison to delta 9- THC-induced interactions with dynorphinergic systems

    Drug Alcohol Depend.

    (1997)
  • Z.-B You et al.

    The striatonigral dynorphin pathway of the rat studied with in vivo microdialysis-II. Effects of dopamine D1 and D2 receptor agonists

    Neuroscience

    (1994)
  • S Akbarian et al.

    Selective alterations in gene expression for NMDA receptor subunits in prefrontal cortex of schizophrenics

    J. Neurosci.

    (1996)
  • M Akil et al.

    Lamina-specific alterations in the dopamine innervation of the prefrontal cortex in schizophrenic subjects

    Am. J. Psychiatry

    (1999)
  • N.C Andreasen

    Linking mind and brain in the study of mental illnessesA project for a scientific psychopathology

    Science

    (1997)
  • R.B Bendel et al.

    Comparison of stopping rules in forward regression

    J. Am. Stat. Assoc.

    (1977)
  • F.M Benes et al.

    Deficits in small interneurons in prefrontal and cingulate cortices of schizophrenic and schizoaffective patients

    Arch. Gen. Psychiatry

    (1991)
  • H.P Blumberg et al.

    Rostral and orbital prefrontal cortex dysfunction in the manic state of bipolar disorder

    Am. J. Psychiatry

    (1999)
  • J.A Bodkin et al.

    Buprenorphine treatment of refractory depression

    J. Clin. Psychopharmacol.

    (1995)
  • L Caberlotto et al.

    Reduced neuropeptide Y mRNA expression in the prefrontal cortex of bipolar subjects

    Neuroreport

    (1999)
  • Cited by (0)

    Present address: Philips Medical Systems B.V., CV Systems Development, Veenpluis 4-6, 5684 PC Best, The Netherlands. E-mail: [email protected]

    View full text